Skip to main navigation Skip to search Skip to main content

A Phase 1/2 Study of ASP1570 as Monotherapy and in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumors

Grants and Contracts Details

StatusActive
Effective start/end date4/8/22 → 1/30/27

Funding

  • Astellas Pharma Global Development Incorporated: $244,013.00